The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 02, 2016

Filed:

Mar. 02, 2012
Applicants:

Jeremiah F. Roeth, Blacksburg, VA (US);

Charles C. Reed, Souderton, PA (US);

Brandon Cuthbertson, Newland, NC (US);

Sunil Chada, Missouri City, TX (US);

William E. Fogler, Rockville, MD (US);

Fayaz Khazi, Frederick, MD (US);

Inventors:

Jeremiah F. Roeth, Blacksburg, VA (US);

Charles C. Reed, Souderton, PA (US);

Brandon Cuthbertson, Newland, NC (US);

Sunil Chada, Missouri City, TX (US);

William E. Fogler, Rockville, MD (US);

Fayaz Khazi, Frederick, MD (US);

Assignee:

Intrexon Corporation, Blacksburg, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/86 (2006.01); C07K 14/505 (2006.01); C07K 14/54 (2006.01); C07K 14/56 (2006.01); C07K 14/565 (2006.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0025 (2013.01); A61K 48/0066 (2013.01); A61K 48/0075 (2013.01); C07K 14/4713 (2013.01); C07K 14/505 (2013.01); C07K 14/5428 (2013.01); C07K 14/5434 (2013.01); C07K 14/56 (2013.01); C07K 14/565 (2013.01); C07K 14/70567 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C07K 2319/70 (2013.01); C07K 2319/715 (2013.01); C07K 2319/81 (2013.01); C12N 2710/10343 (2013.01); C12N 2750/14143 (2013.01); C12N 2830/002 (2013.01); C12N 2830/75 (2013.01); C12N 2830/85 (2013.01); C12N 2840/203 (2013.01);
Abstract

This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.


Find Patent Forward Citations

Loading…